Although we cannot exclude the possibility that interference with these pathways also contributes to the phenotype of USP7-inhibitor-treated cells, we have analyzed the TP53 status in our models and primary AML patient samples and did not observe a loss of effectiveness in TP53 mutant samples. This evidence concerns the gene TP53 and acute myeloid leukemia.